Imunon (LSE:0HUZ) - Aandelenkoers, Nieuws & Analyse

0HUZ Overzicht aandelen

Imunon, Inc., een biotechnologiebedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van immuuntherapieën en vaccins voor de behandeling van kanker en infectieziekten.

Over het bedrijf

0HUZ fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Earnings are forecast to decline by an average of 19.6% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the UK market

+ 2 meer risico's

Imunon, Inc. Concurrenten

OptiBiotix Health

AIM:OPTI

UK£10.0m

ProBiotix Health

OFEX:PBX

UK£11.5m

Synairgen

AIM:SNG

UK£9.6m

LungLife AI

AIM:LLAI

UK£2.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Imunon
Historische aandelenkoersen
Huidige aandelenkoers	US$0.93
52 Week Hoogtepunt	US$3.63
52 Week Laag	US$0.49
Bèta	2.13
11 maand verandering	-9.38%
3 maanden verandering	-20.26%
1 Jaar Verandering	-1.79%
33 jaar verandering	-93.01%
5 jaar verandering	n/a
Verandering sinds IPO	-97.62%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0HUZ	GB Biotechs	GB Markt
7D	0.03%	-0.3%	-1.3%
1Y	-1.8%	-14.6%	8.9%

Rendement versus industrie: 0HUZ exceeded the UK Biotechs industry which returned -14.6% over the past year.

Rendement versus markt: 0HUZ underperformed the UK Market which returned 8.9% over the past year.

Prijsvolatiliteit

Is 0HUZ's price volatile compared to industry and market?
0HUZ volatility
0HUZ Average Weekly Movement	11.3%
Biotechs Industry Average Movement	8.3%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: 0HUZ's share price has been volatile over the past 3 months compared to the UK market.

Volatiliteit in de loop van de tijd: 0HUZ's weekly volatility has decreased from 39% to 11% over the past year, but is still higher than 75% of UK stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1982	33	Stacy Lindborg	imunon.com

Imunon, Inc., een biotechnologiebedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van immuuntherapieën en vaccins voor de behandeling van kanker en infectieziekten. Het belangrijkste klinische programma van het bedrijf, IMNN-001, is een op DNA gebaseerde immuuntherapie voor de plaatselijke behandeling van eierstokkanker die zich in fase II van de klinische ontwikkeling bevindt. De producten in preklinische fase omvatten IMNN-101, een COVID-19 boostervaccin; IMNN-102 voor de behandeling van het Lassa-virus; en IMNN-201, een Trp2 tumorgeassocieerd antigeen kankervaccin in melanoom.

Imunon, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Imunon zich tot de beurswaarde?
0HUZ fundamentele statistieken
Marktkapitalisatie	US$13.68m
Inkomsten(TTM)	-US$18.08m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.8x

Koers/Winstverhouding

Is 0HUZ overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0HUZ resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$359.30k
Brutowinst	-US$359.30k
Overige uitgaven	US$17.72m
Inkomsten	-US$18.08m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 07, 2024

Winst per aandeel (EPS)	-1.26
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 0HUZ op de lange termijn?

Bekijk historische prestaties en vergelijking

0HUZ Overzicht aandelen

Beloningen

Risicoanalyse

Imunon, Inc. Concurrenten

AIM:OPTI

UK£10.0m

OFEX:PBX

UK£11.5m

AIM:SNG

UK£9.6m

AIM:LLAI

UK£2.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Recent updates

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

New major risk - Financial position

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.59 loss per share (vs US$2.19 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Imunon, Inc. Samenvatting

0.0x

-0.8x

Inkomsten en omzet